Inovio Pharmaceuticals, Inc. (INO) stock
Close on Nov 11, 2026Market cap $152.51MP/E –Yield –
Inovio Pharmaceuticals, Inc. grew revenue 63.9% to $298.90K over the twelve months to Sep 30, 2026. Free cash flow was -$74.41M. At the latest close the market valued the company at $152.51M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $152.51M
- P/E ratio
- –
- Price to sales
- 510.24
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -48.79%
Fundamentals
- Revenue
- $298.90K
- Net income
- -$71.14M
- EPS, diluted
- -$0.79
- Free cash flow
- -$74.41M
- Book value per share
- -$0.34
- Diluted shares
- 99M
Trading
- Next earnings
- Mar 11, 2027 (estimated, after the close)
- Previous close
- $1.45
- Open
- $1.37
- Day's range
- $1.30 – $1.48
- Volume
- 10,920,350
- Average volume (20 days)
- 26,962,947
- Beta (5 years)
- 1.58
- 52-week range
- $0.56 – $2.72
- RSI (14 days)
- 56.6
- Volatility (1 year)
- 235.9%
- Relative volume
- 1.23×
- WACC
- 12.8%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | INO | S&P 500 | Difference | INO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +28.3% | -2.4% | +30.7 pts | ||
| 3 months | +92.6% | -1.2% | +93.8 pts | ||
| Year to date | -15.2% | +12.3% | −27.5 pts | ||
| 1 year | -26.2% | +12.4% | −38.7 pts | ||
| 3 years | -64.9% | +78.8% | −143.7 pts | -29.4% | +21.4% |
| 5 years | -98.3% | +75.2% | −173.5 pts | -55.7% | +11.9% |
| 10 years | -98.4% | +311.1% | −409.5 pts | -34.0% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Inovio Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- Results
About Inovio Pharmaceuticals
Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company that develops DNA medicines to treat and prevent human papillomavirus-associated diseases, cancer, and infectious diseases. Its core platform combines engineered circular DNA plasmids with proprietary CELLECTRA electroporation delivery devices to facilitate cellular uptake. The company's lead candidate is INO-3107 for recurrent respiratory papillomatosis, alongside pipeline assets including INO-3112 for throat cancer and INO-5401 for glioblastoma. Because all drug candidates remain in development without commercial sales, the company does not have commercial consumers. Instead, it works with research partners, corporate collaborators, and government entities.
Company profile, executives and historyInovio Pharmaceuticals stock: common questions
What is Inovio Pharmaceuticals's stock price?
INO closed at $1.48 on Nov 11, 2026, up 1.72% on the day. Over the past 52 weeks it traded between $0.56 and $2.72.
What is Inovio Pharmaceuticals's market cap?
Inovio Pharmaceuticals was worth $152.51M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is INO's P/E ratio?
Inovio Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.79), so it has no meaningful P/E ratio.
How much revenue does Inovio Pharmaceuticals make?
Inovio Pharmaceuticals reported revenue of $298.90K for the twelve months to Sep 30, 2026, up 63.9% from a year earlier.
Does Inovio Pharmaceuticals pay a dividend?
No. Inovio Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Inovio Pharmaceuticals report earnings next?
Inovio Pharmaceuticals is expected to report Q4 FY2026 results on Mar 11, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has INO stock performed over the past year?
Including dividends, INO returned -26.2% over the past year, against +12.4% for the S&P 500.
How many INO shares are sold short?
22M shares were sold short at the latest FINRA report, 21.46% of the float, or 1.8 days of average trading volume.
Who are Inovio Pharmaceuticals's competitors?
Companies most similar to Inovio Pharmaceuticals by business, industry and size include NTHI, KZIA, AVTX, LSTA, LNAI.
See a number that looks wrong?